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DOI: 10.1039/c1an15198cThe association of solid phase extraction with molecularly imprinted polymers (MIP) and electrospray
ionization mass spectrometry (ESI-MS) is applied to the direct extraction and quantitation of
benzodiazepines in human plasma. The target analytes are sequestered byMIP and directly analyzed by
ESI-MS. Due to the MIP highly selective extraction, ionic suppression during ESI is minimized; hence
no separation is necessary prior to ESI-MS, which greatly increases analytical speed. Benzodiazepines
(medazepam, nitrazepam, diazepam, chlordiazepoxide, clonazepam and midazolam) in human plasma
were chosen as a proof-of-principle case of drug analyses by MIP-ESI-MS in a complex matrix. MIP-
ESI-MS displayed good figures of merits for medazepam, nitrazepam, diazepam, chlordiazepoxide and
midazolam, with analytical calibration curves ranging from 10 to 250 mg L1 (r > 0.98) with limit of
quantification <10 mg L1 and acceptable within-day and between-day precision and accuracy.Introduction
Mass spectrometry (MS), due to its high selectivity, sensitivity
and speed, is currently the gold standard technique for multi-
target analysis in complex matrices. For precise quantitation,
however, a separation step1,2 is often required prior to MS
analysis in order to avoid ion suppression effects during analyte
ionization. Ion suppression is a common matrix effect in spray
based ionization techniques such as electrospray ionization3 that
causes other components present in the same droplet to hamper
or preclude the ionization of the target analyte.4 Coupling mass
spectrometry with a pre-separation technique permits proper
separation and individual ionization (no competition) from the
ESI droplets and hence more precise quantitation. Selective
extraction also minimizes sample complexity, and consequently
ion suppression,5,6 and solid phase extraction (SPE) has been
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This journal is ª The Royal Society of Chemistry 2011Molecularly imprinted polymers (MIP) are becoming
increasingly more popular for selective extraction from complex
matrices. MIP, first proposed by Wulff and Sarhan,8 are
synthesized for a specific target analyte (template)9 being there-
fore capable of selectively binding via its molded cavities to the
target molecule.10 MIP have been used as sensors,11 stationary
phases for HPLC12 and capillary electrochromatography13 and
for SPE.14,15 Recently, MIP have been coupled to MS such as in
liquid chromatography mass spectrometry,16 ion mobility mass
spectrometry17 and ambient ionization mass spectrometry.7
Screening and detection are greatly simplified and/or improved
by such approaches but for robust quantitation, pre-separation16
or post-separation (via ion mobility)17 has been used and seems
to be an indispensable step.
MIP extracts may allow, however, direct ESI-MS analyses
without pre-separation, since a few molecules of the same class
(or eventually a single molecule) should predominate in such
extracts. Ion suppression during ESI should therefore be greatly
minimized or eliminated. In this study, we tested the application
of MIP-ESI-MS to quantitate target drugs in complex mixtures,
and used benzodiazepines in human plasma as a proof-of-prin-
ciple case.
Experimental
Instrumentation, reagents and solutions
MS analysis was performed using a LCMS 2010 monoquadru-
pole mass spectrometer from Shimadzu Corporation (Kyoto,


























































View Article OnlineThe solutions were prepared with analytical grade chemicals
and deionized water (>18.2 MU cm) obtained from a Milli-Q
water purification system (Millipore, Bedford, USA). For the
MIP synthesis, diazepam was used as the template, methacrylic
acid as the functional monomer, ethylene glycol dimethacrylate
as the crosslinking reagent and 2,20-azobisisobutyronitrile as the
initiator (all from Sigma-Aldrich, Steinheim, Germany). HPLC
grade chloroform (Merck, Darmstadt, Germany) was used as
solvent.
Stock solutions of medazepam, nitrazepam, diazepam, chlor-
diazepoxide, clonazepam and midazolam (all from Sigma-
Aldrich, Steinheim, Germany) were prepared at 7.0 mg L1 in
HPLC grade methanol (J. T. Baker, Phillipsburg, USA). An
aqueous solution of HNO3 (Merck, Darmstadt, Germany) at pH
1.0 was used as the washing solution.Fig. 2 MIP-ESI-MS system used to sequester and quantitate benzodi-
azepines directly from plasma samples. SP: syringe pump, V: three-way
valve, MS: mass spectrometer, W: waste, ESI: electrospray ionization.MIP synthesis
The diazepam-imprinted polymer was prepared according to
Ariffin et al.:18 0.8 mmol of diazepam, 4.6 mmol of methacrylic
acid, 23 mmol of ethylene glycol dimethacrylate and 0.51 mmol
of 2,20-azobisisobutyronitrile were added to a 30 mL glass flask.
The solution was placed in an ice bath and purged with nitrogen
for 5 min. The flask was sealed and a water-bath was used to keep
the temperature at 60 C for 24 h. After polymerization,
the polymer monolith obtained was mechanically ground and the
particle size was selected using a steel sieve (>100 mm). The
template was extracted from the MIP using 10 fractions (10 mL
each) of methanol : acetic acid solution (9 : 1, v/v). The polymer
particles were then dried and maintained at room temperature.
Six benzodiazepines (Fig. 1) were selected as a proof-of-principle
class of drug analytes due to their wide use in conventional
therapy, which routinely requires quantitation in human plasma.Fig. 1 Chemical structures and m/z values of the protonated mole
3754 | Analyst, 2011, 136, 3753–3757Sample preparation
Human plasma samples were submitted to liquid–liquid extrac-
tion (for proteins elimination) using ethyl acetate as solvent:
3 mL of plasma were spiked with 50 mL of benzodiazepine
solution (from 0.6 to 40 mg L1) and 3 mL of 0.1 mol L1 NaOH;
5 mL of ethyl acetate were then added to the test tube which was
vortexed for 1 min and centrifuged at 1000g (15 min). The
organic phase was evaporated under a nitrogen atmosphere. The
residue was then dissolved in 0.5 mL of a 0.01 mol L1 phosphate
buffer, pH 7.0, and then analyzed by MIP-ESI-MS.
All plasma samples were collected after the approval of the
Ethical Committee of the Medical Science Faculty of the
University of Campinas (CAAE: 0411.0.146.000-07).MIP-ESI-MS system
The MIP-ESI-MS system comprises a syringe pump (SP), a MIP
column and a single quadrupole mass spectrometer equipped
with an ESI source (Fig. 2). Each analytical cycle was executed
by pumping through the MIP column: 500 mL of H2O, 500 mL of
sample, 500 mL of washing solution (HNO3, 0.1 mol L
1) andcules for the six benzodiazepine drugs evaluated in this study.


























































View Article Onlinethen 500 mL of H2O at 1 mL min
1. The analytes were presum-
ably retained in the MIP and interferences were eluted by the
wash solution. During washing, the flow originating from the
column was driven to the waste. Soon after, the valve (V) was
switched and the column effluent was then directed to the ESI
source of the mass spectrometer. To promote analyte elution,
500 mL of HNO3 : methanol (1 : 99, v/v) was percolated through
the MIP column at 100 mL min1. ESI mass spectra were
obtained in the positive ion mode and the drugs were detected as
their protonated molecules. System variables were optimized
using a mixed standard solution prepared in aqueous phosphate
buffer containing 200 mg L1 of each benzodiazepine (med-
azepam, nitrazepam, diazepam, chlordiazepoxide, clonazepam
and midazolam). ESI-mass spectra were summed and averaged
for each peak obtained during the elution step.Results and discussions
MIP-ESI-MS optimization
Fig. 3 shows the total ion current (TIC) plot for duplicate
injections of the MIP extract from plasmas spiked with the pool
of benzodiazepines at 200 mg L1. The inset shows the m/z region
of the ESI mass spectrum in which the six drugs are detected via
their protonated molecules. For TIC monitoring, the protonated
molecules of the six drugs (Fig. 1) were used.
Initially, the amount of MIP used to pack the column was
varied to verify the best performance and 20 mg was found to be
ideal. Packing the columns with more than 20 mg of MIP
increases too much the pressure of the system, hampering sample
percolation. Less than 20 mg of MIP decreases sensitivity; for 15,
10 and 5 mg of MIP, TIC intensity decreased by ca. 27, 38 and
55%, respectively.
The eluent composition is important to guarantee the efficient
elution of the analytes from the MIP column as well as for
reconditioning the polymer for the next cycle. To evaluate thisFig. 3 Analytical signals obtained via ESI-MS analysis after sequential
injection (in duplicate) of a human plasma sample spiked with 200 mg L1
of each benzodiazepine drug. The inset shows a full ESI mass spectrum in
which the six drugs are detected via their protonated molecules: med-
azepam (m/z 271), nitrazepam (m/z 282), diazepam (m/z 285), chlordi-
azepoxide (m/z 300), clonazepam (m/z 316) and midazolam (m/z 326).
This journal is ª The Royal Society of Chemistry 2011effect, 1, 5 and 10% (v/v) HNO3 in methanol were tested as
eluent. The results showed that there were no significant changes
in terms of sensitivity (less than 7%) for the three concentrations
tested. Therefore, 1% (v/v) HNO3 in methanol was selected as the
eluent solution, preserving the selective sites of the MIP. It is
important to point out that the nitric acid was used for six
months and no corrosion was observed in the instrument.
Binding between the sorbent and the analyte in SPE is pH
dependent, which influences the ionization (which occurs by
protonation) of the analyte and protonation of the sorbent
binding site.15 Therefore, a phosphate buffer at 0.01 mol L1 was
used, since this buffer has been routinely used for pH stabiliza-
tion of biological samples.7,15 The pH of the sample solution was
varied from 6.0 to 8.0 and the best result for medazepam,
nitrazepam, diazepam, chlordiazepoxide and midazolam, in
terms of sensitivity, was obtained at pH 7.0. Clonazepam showed
little changes in response as a function of pH. Coincidentally, this
molecule is inefficiently retained in the diazepam–MIP. A
possible explanation for this low adsorption is the o-chloride
substitution that may hinder proper fitting in the MIP cavities.
During the extraction step, other molecules than the target
analytes can bind to the MIP either in the specific binding site
(molecules similar to the template) or binding can also occur with
much less selectivity to the polymer surface (dissimilar mole-
cules).19,20 This problem can be circumvented using acidic or
alkaline washing solutions at high enough concentrations to
eliminate these concomitants but the washing solution should be
also selective and not remove the target analytes. In this work, an
aqueous HNO3 solution was used to wash the MIP and its pH
was evaluated for optimal concomitant removal. The pH was
varied from 1.0 to 4.0, and the best result was obtained for pH
1.0. For pH < 1.0, a considerable decrease in sensitivity was
observed for all analytes.Fig. 4 ESI mass spectra of a human plasma sample spiked with the pool
of six benzodiazepines at 100 mg L1 and analyzed either after (A) liquid–
liquid extraction or (B) liquid–liquid extraction followed by MIP
extraction.
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Table 1 Linear equations, correlation coefficients (r) and ranges (n ¼ 3)
obtained for the determination of six benzodiazepines in plasma by MIP-
ESI-MS
Benzodiazepines Linear equation r Range/mg L1
Medazepam y ¼ 230x + 2927 0.980 10–250
Nitrazepam y ¼ 283x + 7442 0.986 10–250
Diazepam y ¼ 494x + 3914 0.994 10–250
Chlordiazepoxide y ¼ 451x + 3164 0.984 10–250
Clonazepam y ¼ 63x + 11 390 0.745 10–250
Midazolam y ¼ 1297x  7602 0.977 10–250









HPLC-MS SPEa 2 6.8 22
CE-UV LLEb 3 20 23
CG-MS SPMEc 3.5 10 24
HPLC-UV SPE 4.8 2.5 25
MIP-ESI-MS MISPE 12 10 This paper



























































View Article OnlineSelectivity study
MIP selectivity was checked using a human plasma sample
fortified with all six benzodiazepines (150 mg L1). For compar-
ison, ESI-MS analysis was performed after: (a) simple liquid–
liquid extraction or (b) liquid–liquid extraction followed by MIP
extraction. For liquid–liquid extraction only (Fig. 4A), ions of
the target drugs were not observed, perhaps due to great sample
complexity and therefore considerable ion suppression during
ESI. But for liquid–liquid plus MIP extraction, however, abun-
dant benzodiazepine ions were observed (Fig. 4B) likely due to
much reduced ion suppression. This result confirms that selective
MIP extraction is essential to eliminate concomitants present in
high concentrations in the plasma sample as well as in the liquid–
liquid extract, avoiding substantial ion suppression during ESI.Fig. 5 MIP-ESI mass spectra of a plasma sample spiked with the pool of
the six benzodiazepines at (A) 10 mg L1, (B) 100 mg L1 or (C) 200 mg L1.
Note the detection of all six drugs as their protonated molecules: med-
azepam (m/z 271), nitrazepam (m/z 282), diazepam (m/z 285), chlordi-
azepoxide (m/z 300), clonazepam (m/z 316) and midazolam (m/z 326), and
the rather clean mass spectra obtained from complex plasma matrices.
3756 | Analyst, 2011, 136, 3753–3757Figures of merit
The analytical curves, which were prepared using a pool of
human plasma, presented linear ranges from 10 to 250 mg L1 for
medazepam, nitrazepam, diazepam, chlordiazepoxide and mid-
azolam (Table 1). Higher concentrations resulted in linearity
deviation, probably due toMIP saturation. Fig. 5 shows ESI-MS
for three plasma samples spiked with 10, 100 and 200 mg L1 of
the six benzodiazepines. Note the rather clean mass spectra
obtained from complex plasma matrices and the proper detection
of all six drugs of the pool. Poor linearity was observed for
clonazepam, probably due to the low retention capacity of the
MIP to sequester this molecule as described in MIP-ESI-MS
optimization. The limit of quantitation (LOQ), calculated as ten
times the noise level of the blank, was ca. 10 mg L1 for med-
azepam, nitrazepam, diazepam, chlordiazepoxide and mid-
azolam. The speed of analysis was calculated as 12 samples per
hour (MIP extraction plus ESI-MS).
Precision and accuracy (intra-day and inter-day) were
measured as the relative standard deviation (RSD) and relative
error (E), respectively, using a human plasma sample spiked with
150 mg L1 of each benzodiazepine. The RSD and E values (both
for n ¼ 5) ranged from 9 to 18% and 7 to 18%, respectively, in
agreement with FDA (Food and Drug Administration) guide-
lines.21 The same MIP column was used during all optimization
and validation steps and non-significant differences (<10%) were
observed in the analytical signal after ca. 70 cycles.Conclusions
Short filters packed with properly designed MIP can be advan-
tageously used for fast sample clean-up and to sequester specific
classes of target molecules from complex biological matrices
during drug analysis by direct infusion ESI-MS. Ion suppression
is greatly minimized (or nearly eliminated) and quite equal
ionization efficiencies are attained due to selective extraction of
target molecules of the same class. These features permit proper
quantitation in short times (ca. 5 min or less by analysis) with no
prior separation steps. The MIP-ESI-MS method, as exemplified
here for medazepam, nitrazepam, diazepam, chlordiazepoxide
and midazolam in human plasma, presents good figures of merits
in terms of precision, accuracy, LOQ, and speed of analysis
(Table 2). The MIP-ESI-MS coupling seems therefore promising
for high throughput analyses of target molecules in complex
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